Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

BACKGROUND: Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinic...

Full description

Bibliographic Details
Main Authors: Chan, Kelvin, Nam, Seungree, Evans, Bill, de Oliveira, Claire, Chambers, Alexandra, Gavura, Scott, Hoch, Jeffrey, Mercer, Rebecca E, Dai, Wei Fang, Beca, Jaclyn, Tadrous, Mina, Isaranuwatchai, Wanrudee
Format: Online Article Text
Language:English
Published: BMJ Publishing Group 2020
Subjects:
Health Economics
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955501/
https://www.ncbi.nlm.nih.gov/pubmed/31915169
http://dx.doi.org/10.1136/bmjopen-2019-032884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6955501/
https://www.ncbi.nlm.nih.gov/pubmed/31915169
http://dx.doi.org/10.1136/bmjopen-2019-032884

Similar Items